A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: A complete response to targeted therapy

3Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Sarcomatoid melanoma is an extremely rare pattern of malignant melanoma, and only few cases have been described throughout the literature. We herein report a case of a patient with newly diagnosed, metastatic giant sarcomatoid melanoma of the arm. The patient underwent surgical removal of the huge mass, and NGS sequencing demonstrated BRAF V600E mutation. In view of histological, immunohistochemical and molecular findings, a combined BRAF/MEK inhibitor (BRAF/MEK-i) therapy was prescribed as first line treatment. A complete response (over one year) to targeted therapy was obtained, and no adverse events have been reported. The patient maintained a full range of shoulder and elbow movements, and she is able to live independently and resume her daily activities. We therefore recommend that all patients with undifferentiated melanomas, sarcomatoid cutaneous malignancies or other mesenchymal tumours, should undergo BRAFV600E mutation testing.

Cite

CITATION STYLE

APA

Torresetti, M., Brancorsini, D., Morgese, F., Cognigni, V., Scalise, A., Berardi, R., & Di Benedetto, G. (2020). A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: A complete response to targeted therapy. Oncotarget, 11(34), 3256–3262. https://doi.org/10.18632/oncotarget.27701

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free